today's Pick
Ebola vaccine trials being fast-tracked: researchers
Publish Date: Aug 28, 2014
Ebola vaccine trials being fast-tracked: researchers
Nigeria warns against complacency in Ebola fight A man reads a poster raising awareness on the Ebola virus reading "the risk of Ebola is still there. Let us apply the protective measures together" in Abidjian, Ivory Coast
  • mail
  • img
newvision

Safety trials on an Ebola vaccine are being fast-tracked, meaning it could be given to healthy volunteers as early as September, researchers said Thursday.

The vaccine will be given to volunteers in Britain, the Gambia and Mali in a bid to tackle the spread of an epidemic which has spread across west Africa, killing 1,552 so far.

Researchers hope the trials could finish by the end of 2014.

If they are successful, the vaccine could then be given to people infected with Ebola, which is spread through bodily fluids.

The move was announced by pharmaceuticals giant GlaxoSmithKline -- which is developing the vaccine with the US National Institutes of Health (NIH) -- and London-based medical charity Wellcome Trust, which is contributing to a grant to pay for the trials.

"A candidate Ebola vaccine could be given to healthy volunteers in the UK, the Gambia and Mali as early as September, as part of a series of safety trials of potential vaccines," the statement said.

A total of 3,062 cases have so far been reported but the World Health Organization warned Thursday that the caseload could eventually exceed 20,000.

The trials, which still need ethical and regulatory approval, will be funded by a £2.8 million (3.5 million euro, $4.6 million) grant from the Wellcome Trust, Britain's Medical Research Council (MRC) and the UK Department for International Development (DFID).

The Oxford study will involve 60 healthy volunteers, while those in the Gambia and Mali will each involve 40.

This will also allow GSK to make some 10,000 extra doses of the vaccine so that if the trials are successful, it could be made available to the WHO quickly.

Safety tests of the vaccine will take place at Oxford University alongside a US trial run by the National Institute of Allergy and Infectious Diseases. AFP  (NIAID). AFP

The statements, comments, or opinions expressed through the use of New Vision Online are those of their respective authors, who are solely responsible for them, and do not necessarily represent the views held by the staff and management of New Vision Online.

New Vision Online reserves the right to moderate, publish or delete a post without warning or consultation with the author.Find out why we moderate comments. For any questions please contact digital@newvision.co.ug

  • mail
  • img
blog comments powered by Disqus
Also In This Section
Wavamunno: Making of a successful businessman
From humble beginnings, Gordon Wavamunno has managed to not only survive, but thrive as a businessman....
AFCON qualifier: Comoros v Uganda
If Cranes hope to progress to the 2017 Nations Cup finals, they will have to gather a minimum of 12 points to progress....
Gulu to start mass anti-malaria treatment
Gulu district is to embark on mass fever treatment as a strategy to bring down the rising cases of malaria in the district....
Mbabazi releases new consultation programme
Former Prime Minister, Amama Mbabazi has released his new programme for consultations....
Media asked to promote sex education
The media is asked to promote sex education to curb teenage pregnancies, child mothers, abortions and other related sexual vices....
All Africa Games start
The 11th edition of the All Africa Games officially start today, with Uganda represented in Congo Brazzaville....
Are poor parliamentary debates a result of removal of school debates?
Yes
No
Can't Say
follow us
subscribe to our news letter